



Deciphera Pharmaceuticals to Present at JMP Securities Life Sciences Conference

June 16, 2016

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera's President and Chief Executive Officer will present a corporate update at the upcoming JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 3:00 p.m. ET in New York.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.

Contacts:

Deciphera Pharmaceuticals

Michael D. Taylor, Ph.D., 781-209-6411

mtaylor@deciphera.com

Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com